What is the price target for HAE stock?
15 analysts have analysed HAE and the average price target is 89.76 USD. This implies a price increase of 58.42% is expected in the next year compared to the current price of 56.66.
NYSE:HAE • US4050241003
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HAEMONETICS CORP/MASS (HAE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-02-06 | Barrington Research | Maintains | Outperform -> Outperform |
| 2026-02-06 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-02-06 | BTIG | Reiterate | Buy -> Buy |
| 2026-02-06 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-02-02 | Barrington Research | Maintains | Outperform -> Outperform |
| 2026-01-12 | Barrington Research | Maintains | Outperform -> Outperform |
| 2026-01-09 | BTIG | Reiterate | Buy -> Buy |
| 2025-12-17 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-15 | Needham | Downgrade | Buy -> Hold |
| 2025-12-15 | Baird | Maintains | Outperform -> Outperform |
| 2025-12-12 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-12-11 | Citigroup | Downgrade | Buy -> Neutral |
| 2025-11-21 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-07 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-11-07 | Needham | Maintains | Buy -> Buy |
| 2025-11-06 | BTIG | Maintains | Buy -> Buy |
| 2025-10-21 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-10-07 | Citigroup | Maintains | Buy -> Buy |
| 2025-09-23 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-08-11 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2025-08-08 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-08-08 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-08-08 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-08-07 | Needham | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.169B 17.67% | 1.309B 12.01% | 1.361B 3.95% | 1.338B -1.68% | 1.409B 5.31% | 1.503B 6.67% | |
| EBITDA YoY % growth | 261.5M 31.87% | 310.449M 18.72% | 360.834M 16.23% | 432.78M 19.94% | 439.24M 1.49% | 488.65M 11.25% | |
| EBIT YoY % growth | 168.2M 67.20% | 213.234M 26.77% | 245.248M 15.01% | 348.17M 41.97% | 375.49M 7.85% | 410.82M 9.41% | |
| Operating Margin | 14.39% | 16.29% | 18.02% | 26.02% | 26.65% | 27.33% | |
| EPS YoY % growth | 3.03 16.99% | 3.98 31.35% | 4.57 14.82% | 5.00 9.31% | 5.37 7.60% | 5.92 10.12% |
All data in USD
| Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.28 3.58% | 1.18 6.99% | 1.40 10.49% | 1.41 7.94% | 1.48 15.12% | 1.35 15.00% | 1.65 17.33% | 1.68 18.57% | 1.67 12.70% |
| Revenue Q2Q % growth | 340.41M 2.97% | 336.23M 4.62% | 352.6M 7.72% | 358.08M 5.64% | 362.04M 6.35% | 356.31M 5.97% | 376.52M 6.78% | 379.57M 6.00% | 377.81M 4.36% |
| EBITDA Q2Q % growth | 105.44M -39.52% | 97.46M 4.02% | 116.01M -6.66% | 118M -23.36% | 121.66M 15.38% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 91.518M 55.77% | 84.082M 29.48% | 98.422M 46.29% | 99.237M 42.66% | 101.59M 11.01% | 93.351M 11.02% | 110.58M 12.35% | 111.84M 12.70% | 110.76M 9.03% |
All data in USD
15 analysts have analysed HAE and the average price target is 89.76 USD. This implies a price increase of 58.42% is expected in the next year compared to the current price of 56.66.
HAEMONETICS CORP/MASS (HAE) will report earnings on 2026-05-06, after the market close.
The consensus EPS estimate for the next earnings of HAEMONETICS CORP/MASS (HAE) is 1.28 USD and the consensus revenue estimate is 340.41M USD.
The expected long term growth rate for HAEMONETICS CORP/MASS (HAE) is 3.06%.